MEDIAN Technologies announced that it has signed a contract with a San Francisco-area based biotech company
MEDIAN Technologies, a medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced that it has signed a contract with a San Francisco-area based biotech company to provide imaging services to support a phase II clinical trial for advanced non-small cell lung cancer.
The study is anticipating imaging data from 90 clinical sites, based in 12 European countries, in the US, and in Canada. Anticipated total enrollment is 440 patients with a "first patient in" forecasted May 2014. Median will supply a set of services including clinical site qualification and training, as well as image and data collection, quality control, and storage.
Read the full release here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.